The FDA cleared emergency use of the two vaccines on Friday, which was swiftly followed by a recommendation from a Centres for Disease Control and Prevention (CDC) advisory committee that was swiftly signed off by CDC director Rochelle Walensky.
The Advisory Committee on Immunization Practices (ACIP) recommended that a third dose of Pfizer/BioNTech’s Comirnaty or Moderna’s mRNA-1273 be given at least six months after the second dose.
The panel also strengthened its recommendations for fully vaccinated people in the 50 to 64 age group, saying that all people in this age group should receive a booster whether or not they have an underlying health condition that could make them vulnerable to severe COVID-19.
